RBS-2418 by Riboscience for Hepatocellular Carcinoma: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RBS-2418 overview
RBS-2418 is under development for treatment of solid tumor, advanced unresectable, recurrent or refractory metastatic adrenal cancer, colorectal cancer, hepatocellular carcinoma. The therapeutic candidate is a selective small molecule inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1). It is administered by oral route.
For a complete picture of RBS-2418’s drug-specific PTSR and LoA scores, buy the report here.
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Source link
#RBS2418 #Riboscience #Hepatocellular #Carcinoma #Likelihood #Approval
